Terbium-161 production and quality control

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F24%3A00378184" target="_blank" >RIV/68407700:21340/24:00378184 - isvavai.cz</a>

Výsledek na webu

<a href="https://events.ncbj.gov.pl/event/322/attachments/601/976/Book_of_abstracts.pdf" target="_blank" >https://events.ncbj.gov.pl/event/322/attachments/601/976/Book_of_abstracts.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Terbium-161 production and quality control

Popis výsledku v původním jazyce

Terbium-161 is a promising radionuclide for medicinal use. Its physical characteristics make it a great candidate for theranostic use. It decays with half-life of 6,89 days while emitting beta minus particles with maximum energy 593 keV and avarege energy 154 keV. Tb-161 also emits 12,4 conversion and Auger electrons per decay which enhances its therapeutic efficiency. In addition, gamma radiation with energy 74 keV is emitted, which can be used for SPECT imaging1. No carrier added terbium-161 can be prepared by irradiating Gd in form of oxide or nitrate highly enriched with 160Gd in nuclear reactor. Terbium-161 was produced by irradiation of highly enriched gadolinium-160 (98,6 %) in the oxide form in the nuclear reactor LVR 15 (CV Řež). Terbium-161 was separated by cation exchange chromatography with the resin Dowex 50Wx8 with alpha-hydroxyisobutyric acid (αHIBA) as eluent. Collected fraction were repurified from α-HIBA on a smaller column using the same cation exchange resin. The purity of prepared Tb-161 was verified by gamma spectrometry on an HPGe detector and by ICP-MS. Quality control of Tb-161 solution was evaluated by radiolabelling DOTA molecule in various molar ratios of Tb: DOTA in various time periods after the end of separation. One batch typically yields 3,9 – 22 GBq of no carried added 161-Tb with radionuclide purity higher than 99,999 %, which is sufficient as 1 – 3 therapeutical doses.

Název v anglickém jazyce

Terbium-161 production and quality control

Popis výsledku anglicky

Terbium-161 is a promising radionuclide for medicinal use. Its physical characteristics make it a great candidate for theranostic use. It decays with half-life of 6,89 days while emitting beta minus particles with maximum energy 593 keV and avarege energy 154 keV. Tb-161 also emits 12,4 conversion and Auger electrons per decay which enhances its therapeutic efficiency. In addition, gamma radiation with energy 74 keV is emitted, which can be used for SPECT imaging1. No carrier added terbium-161 can be prepared by irradiating Gd in form of oxide or nitrate highly enriched with 160Gd in nuclear reactor. Terbium-161 was produced by irradiation of highly enriched gadolinium-160 (98,6 %) in the oxide form in the nuclear reactor LVR 15 (CV Řež). Terbium-161 was separated by cation exchange chromatography with the resin Dowex 50Wx8 with alpha-hydroxyisobutyric acid (αHIBA) as eluent. Collected fraction were repurified from α-HIBA on a smaller column using the same cation exchange resin. The purity of prepared Tb-161 was verified by gamma spectrometry on an HPGe detector and by ICP-MS. Quality control of Tb-161 solution was evaluated by radiolabelling DOTA molecule in various molar ratios of Tb: DOTA in various time periods after the end of separation. One batch typically yields 3,9 – 22 GBq of no carried added 161-Tb with radionuclide purity higher than 99,999 %, which is sufficient as 1 – 3 therapeutical doses.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10402 - Inorganic and nuclear chemistry

Projekt

<a href="/cs/project/TO01000074" target="_blank" >TO01000074: Účinná terapie nádorových onemocnění nízkoenergetickými elektrony terbia-161.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů